Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04504773 · ClinicalTrials.gov registry record · NA
Using Immersive Virtual Reality to Treat Pediatric Anxiety
A NA study of Specific Phobia and Specific Phobia, Animal, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT04504773: Completed NA study of Specific Phobia and Specific Phobia, Animal, sponsored by Johns Hopkins University.
NCT04504773 is a NA study of Specific Phobia and Specific Phobia, Animal that has completed, run by Johns Hopkins University. The registered enrollment target is 3 participants, below the 201-participant average among 5 other Specific Phobia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04504773, a NA study of Specific Phobia and Specific Phobia, Animal, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
Anxiety is a common and impairing problem for children. The principle treatment for pediatric anxiety involves facing a child's fears in a stepwise approach through a therapeutic exercise called exposures. While exposures are effective, some feared situations cannot be confronted in a clinician's office (e.g., heights, public speaking, storms). This poses a logistical challenge in treatment that: (1) takes time away from patient care, (2) leads clinicians to rely on imagined exposures, and/or (3) requires families to complete exposures outside of the therapy visits. This creates a burden for clinicians and families, and impedes treatment success. Immersive virtual reality (VR) presents an innovative solution that allows children to face fears without leaving the clinician's office. While VR has been used to distract children during painful medical procedures, it has not been well examined as a primary treatment for pediatric anxiety. This study proposes to examine the effectiveness and acceptability of using immersive VR exposures to treat children and adolescents with specific phobias.
Primary Outcome
The ADIS-C/P CSR for the Specific Phobia is a single item rating that is made by a clinician. Scores are made on a 9-point scale that ranges from 0 (Not at all) to 8 (Very, very much). A score of 4 or greater considered to be indicative of a psychiatric disorder.
Conditions Studied
Interventions
- BEHAVIORAL Virtual Reality Exposure Therapy
Study Locations (1)
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-09-17 |
| Est. Completion | 2023-02-14 |
| Phase | NA |
What the finished NCT04504773 record still lists
NCT04504773 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 201-participant average among 5 other Specific Phobia trials with a reported enrollment target (99% lower).
The record links to 5 conditions, with Specific Phobia appearing as the primary indexed condition, and to 1 intervention - of which Virtual Reality Exposure Therapy is the first listed.
NCT04504773 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04504773 about?
NCT04504773 is a clinical study titled "Using Immersive Virtual Reality to Treat Pediatric Anxiety". Anxiety is a common and impairing problem for children. The principle treatment for pediatric anxiety involves facing a child's fears in a stepwise approach through a therapeutic exercise called exposures. While exposures are effective, some feared situations cannot be confronted in a clinician's of...
What is the current status of trial NCT04504773?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2020-09-17. Estimated completion is 2023-02-14.
What conditions does trial NCT04504773 study?
This clinical trial studies the following conditions: Specific Phobia, Specific Phobia, Animal, Childhood Anxiety Disorder, Specific Phobia, Situational, Specific Phobia, Natural Environment.
What interventions are being tested in trial NCT04504773?
The interventions under investigation include: Virtual Reality Exposure Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT04504773?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04504773 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Specific Phobia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stepped Care Treatment for Anxiety Resilience
RECRUITING · NA
-
Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
COMPLETED · NA
-
Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics
COMPLETED · NA
-
Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders
COMPLETED · NA
-
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI